Clarus Ventures has a two-pronged, "roughly equal-weighted" strategy with its latest fund, Clarus III, which closed at $500 million, well above the targeted $375 million, managing director Scott Requadt told BioWorld Today: therapeutics-focused companies at all stages, with breakthrough science and/or best-in-class assets, and R&D risk-sharing partnerships with the pharmaceutical and biotech industries.